SAKK 23/16 / IBCSG 57-18 / ABCSG-53. Tailored AXIllary
Surgery with or without axillary lymph node dissection followed
by radiotherapy in patients with clinically node-positive breast
cancer (TAXIS).

A multicenter randomized phase III trial.

The removal of all lymph nodes in the armpit through conventional
axillary dissection has been standard care for all patients with breast
cancer for almost a century. In the nineties, the sentinel lymph node
(SLN) procedure, which involves the selective removal of the first
few lymph nodes in the lymphatic drainage system, was introduced
in clinical practice. Today, conventional axillary dissection is still
performed on many women with breast cancer that has spread to
the nodes. It is the cause for relevant morbidity in the form of
lymphedema, impairment of shoulder mobility, sensation disorders
and chronic pain in as much as one third of all women undergoing
the procedure.

The TAXIS trial will evaluate the optimal treatment for breast cancer
patients with confirmed nodal disease at first diagnosis in terms of
surgery and radiotherapy. In particular, it will investigate the value of
tailored axillary surgery (TAS), a new technique that aims at
selectively removing the positive lymph nodes. TAS is a promising
procedure that may significantly decrease morbidity in breast cancer
patients by avoiding surgical overtreatment.
This trial has the potential to establish a new worldwide treatment
standard with hopefully less side effects and a better quality of life,
while keeping the same efficacy as provided by radical surgery.

    Coordinating Investigator
    Prof. Dr. med. Walter P. Weber
    University Hospital Basel,
    Spitalstrasse 21
    CH – 4051 Basel
    Phone: +41 61 328 61 49
    Fax: +41 61 265 77 92
    This email address is being protected from spambots. You need JavaScript enabled to view it.


    Trial Coordinator

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Swiss Group for Clinical Cancer Research (SAKK)
    Bern, Switzerland
    Phone:  +41 31 389 91 91
    Fax: +41 31 508 41 42
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Targeted Accrual
    1500

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login